



EPICS

LYMPHOMA IN 2020 AND BEYOND

September 29 and October 1, 2020

FACULTY EXPERTS

Chair
Brad Kahl, MD



Stefan Barta, MD,
MS, MRCPCUK



Paolo Caimi, MD



Catherine Diefenbach, MD



Kieron Dunleavy, MD



Peter Martin, MD



Nina Wagner-Johnston, MD

AGENDA: PART 1 – SEPTEMBER 29, 2020

EPICS

Time	Topic	Speaker/Moderator
7.00 PM – 7.10 PM (10 min)	Welcome and Introductions	Brad Kahl, MD
7.10 PM – 7.25 PM (15 min)	Current and Evolving Treatments for T-Cell Lymphomas (peripheral T-cell lymphomas, adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma)	Stefan Klaus Barta, MD, MS, MRCP(UK)
7.25 PM – 7.55 PM (30 min)	Key Questions and Topics for Discussion	
7.55 PM – 8.05 PM (10 min)	Current and Evolving Treatments for Hodgkin Lymphoma	Catherine Diefenbach, MD
8.05 PM – 8.35 PM (30 min)	Key Questions and Topics for Discussion	
8.35 PM – 8.45 PM (10 min)	<i>BREAK</i>	
8.45 PM – 9.00 PM (15 min)	Current and Evolving Treatments for MZL/Waldenström Macroglobulinemia	Nina D. Wagner-Johnston, MD
9.00 PM – 9.30 PM (30 min)	Key Questions and Topics for Discussion	
9.30 PM – 9.50 PM (20 min)	Round-robin and Discussion on Treating Lymphoma in the COVID-19 Era	Brad Kahl, MD moderating
9.50 PM – 10.00 PM (10 min)	Wrap-up and Overview	Brad Kahl, MD

CURRENT AND EVOLVING TREATMENTS FOR T-CELL LYMPHOMAS: OVERVIEW (1/2) (STEFAN KLAUS BARTA)

EPICS

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR T-CELL LYMPHOMAS: OVERVIEW (2/2) (STEFAN KLAUS BARTA)

EPICS

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR T-CELL LYMPHOMAS: DISCUSSION HIGHLIGHTS (1/3)

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR T-CELL LYMPHOMAS: DISCUSSION HIGHLIGHTS (2/3)

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR T-CELL LYMPHOMAS: DISCUSSION HIGHLIGHTS (3/3)

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR HODGKIN LYMPHOMA: OVERVIEW (1/2) (CATHERINE DIEFENBACH)

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR HODGKIN LYMPHOMA: OVERVIEW (2/2) (CATHERINE DIEFENBACH)

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR HODGKIN LYMPHOMA: DISCUSSION HIGHLIGHTS (1/2)

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR HODGKIN LYMPHOMA: DISCUSSION HIGHLIGHTS (2/2)

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR MZL/ WALDENSTRÖM MACROGLOBULINEMIA: OVERVIEW (1/2)

(NINA D. WAGNER-JOHNSTON)

EPICS

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR MZL/ WALDENSTRÖM MACROGLOBULINEMIA: OVERVIEW (2/2)

(NINA D. WAGNER-JOHNSTON)

EPICS

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR MZL/ WALDENSTRÖM MACROGLOBULINEMIA: DISCUSSION (1/3)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR MZL/ WALDENSTRÖM MACROGLOBULINEMIA: DISCUSSION (2/3)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR MZL/ WALDENSTRÖM MACROGLOBULINEMIA: DISCUSSION (3/3)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

TREATING LYMPHOMA IN THE COVID-19 ERA: DISCUSSION (1/2)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

TREATING LYMPHOMA IN THE COVID-19 ERA: DISCUSSION (2/2)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

AGENDA: PART 2 – OCTOBER 1, 2020

Time	Topic	Speaker/Moderator
7.00 PM – 7.05 PM (5 min)	Agenda Review	Brad Kahl, MD
7.05 PM – 7.15 PM (10 min)	Current and Evolving Treatments for DLBCL	Paolo Caimi, MD
7.15 PM – 7.50 PM (35 min)	Key Questions and Topics for Discussion	
7.50 PM – 8.00 PM (10 min)	Current and Evolving Treatments for FL	Kieron Dunleavy, MD
8.00 PM – 8.25 PM (25 min)	Key Questions and Topics for Discussion	
8.25 PM – 8.35 PM (10 min)	<i>BREAK</i>	
8.35 PM – 8.45 PM (10 min)	Current and Evolving Treatments for CLL/SLL	Brad Kahl, MD
8.45 PM – 9.10 PM (25 min)	Key Questions and Topics for Discussion	
9.10 PM – 9.20 PM (10 min)	Current and Evolving Treatments for MCL	Peter Martin, MD
9.20 PM – 9.45 PM (25 min)	Key Questions and Topics for Discussion	
9.45 PM – 10.00 PM (15 min)	Wrap-up and Overview	Brad Kahl, MD

CURRENT AND EVOLVING TREATMENTS FOR DLBCL: OVERVIEW (1/2) (PAOLO CAIMI)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR DLBCL: OVERVIEW (2/2) (PAOLO CAIMI)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR DLBCL: DISCUSSION HIGHLIGHTS (1/5)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR DLBCL: DISCUSSION HIGHLIGHTS (2/5)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR DLBCL: DISCUSSION HIGHLIGHTS (3/5)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR DLBCL: DISCUSSION HIGHLIGHTS (4/5)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR DLBCL: DISCUSSION HIGHLIGHTS (5/5)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

(1/2) (KIERON DUNLEAVY)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR FL: OVERVIEW

(2/2) (KIERON DUNLEAVY)

EPICS

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR FL: DISCUSSION HIGHLIGHTS (1/2)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR FL: DISCUSSION HIGHLIGHTS (2/2)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR CLL/SLL: OVERVIEW (1/2) (BRAD KAHL)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR CLL/SLL: OVERVIEW (2/2) (BRAD KAHL)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR CLL/SLL: DISCUSSION HIGHLIGHTS (1/3)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR CLL/SLL: DISCUSSION HIGHLIGHTS (2/3)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR CLL/SLL: DISCUSSION HIGHLIGHTS (3/3)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR MCL: OVERVIEW (1/2) (PETER MARTIN)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR MCL: OVERVIEW (2/2) (PETER MARTIN)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR MCL: DISCUSSION HIGHLIGHTS (1/4)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR MCL: DISCUSSION HIGHLIGHTS (2/4)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR MCL: DISCUSSION HIGHLIGHTS (3/4)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CURRENT AND EVOLVING TREATMENTS FOR MCL: DISCUSSION HIGHLIGHTS (4/4)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT